Evidence map›Paper›PMID 33525313›Full record

ReviewNeurology international2021

Ubrogepant to Treat Acute Migraine in Adults.

Amber N Edinoff, C Austin Casey, Marc A Colon, Alexa R Zaheri, Courtney M Gregoire, Margaret M Bourg, Alan D Kaye, Jessica S Kaye, Adam M Kaye, Rachel J Kaye and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Amber N EdinoffDepartment of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0001-7436-6206
C Austin CaseyDepartment of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Marc A ColonDepartment of Psychiatry and Behavioral Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Alexa R ZaheriShreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA.
Courtney M GregoireShreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA.
Margaret M BourgShreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0003-2464-0187
Jessica S KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA.ORCID 0000-0002-7224-3322
Rachel J KayeSchool of medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Sridhar R TirumalaDepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA.
Omar ViswanathDepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA.
Ivan UritsDepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0002-3652-6085
Louisiana State University in Shreveport · USUniversity of the Pacific · USCreighton University · USMedical University of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a neurobiological headache disorder that affects around 16% of adults in the United States. Medical treatment of mild to moderate migraines include non-prescription non-steroidal anti-inflammatory drugs, acetaminophen, or aspirin and caffeine-containing combination analgesics. Additionally, moderate to severe migraines and those that are mild to moderate that have not responded to analgesics can be treated with triptans, which are drugs specific for migraine treatment. Non-pharmacological treatments include cognitive behavioral therapy and relaxation training. Medications for the prevention of migraines have also been developed since they are more affective in offsetting the symptoms. Ubrogepant's high specificity and selectivity for calcitonin gene-related peptide (CGRP) sets it apart from certain other drugs, which previously limited the treatment of migraines with or without aura due to their decreased selectivity. The most frequently reported side effects are oropharyngeal pain, nasopharyngitis, and headache. Most studies found that participants receiving Ubrogepant were free from pain within 2 h when compared to placebo. Patients taking Ubrogepant should avoid taking it when pregnant or with end stage renal disease. In summary, Ubrogepant has good tolerability and an overall favorable safety profile. It appears to hold promise for the acute treatment of migraines with or without aura in adults.

Indexed as

abortive treatmentCGRP inhibitorsmigrainesmigraine treatmentubrogepant

Identifiers

PMID33525313
PMCPMC7931025
OpenAlexW3123838670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.